ClinicalTrials.gg
CompletedNCT00761657Updated Nov 19, 2021Results posted

Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis

A Phase 2 interventional study of Roxadustat and Placebo in Chronic Kidney Disease and Anemia, sponsored by FibroGen. Completed at 34 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-11-19.

Sponsored by FibroGen · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Nov 2006, registered Sep 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing roxadustat in Renal Insufficiency, Chronic — none open to participants now, 1 under way, 1 of them phase 3. roxadustat · Renal Insufficiency, Chronic.

Enrollment
13th of 19
117 · median 161
Started
2006
the only one that year
Phase 2
4 of 19
none open now
Registered
1st of 19
by date
Lead sponsor
10 of 19
FibroGen

Among the 19 studies testing roxadustat in Renal Insufficiency, Chronic, this one is the 13th largest by enrollment, is the only one that started in 2006, is one of 4 in phase 2, and was the 1st registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

None of the 19 studies testing roxadustat in Renal Insufficiency, Chronic is open now. The open studies under Renal Insufficiency, Chronic, anywhere →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing roxadustat in Renal Insufficiency, Chronic as a file.
02

Study summary

The primary objective of the study is to evaluate the safety, tolerability, and pharmacodynamic effects of different oral doses of roxadustat administered 2 times a week (BIW) or 3 times a week (TIW) for up to 4 weeks to participants with chronic kidney disease (CKD) not requiring dialysis.

Read the detailed description

This study in participants with CKD not requiring dialysis was conducted in 2 parts (designated Part 1 and Part 2). Part 1 evaluated roxadustat doses at 1.0 and 2.0 milligrams/kilograms (mg/kg). Part 2 evaluated roxadustat doses at 0.7, 1.5, and 2.0 mg/kg.

On 08 May 2007, the Food and Drug Administration (FDA) placed a clinical hold on the study until evaluation of a report of a death due to fulminant hepatic failure in a participant with CKD in a FibroGen-sponsored clinical trial of another hypoxia inducible factor-prolyl hydroxylase inhibitor (HIF-PHI) (FG-2216) being investigated for treatment of anemia in participants with CKD and other diseases. The clinical hold resulted in early termination of Part 1 of the study. On 24 March 2008, the FDA lifted the clinical hold and Part 2 of this study started.

03

Conditions studied

  • Chronic Kidney Disease
  • Anemia

Keywords

  • Kidney
  • Chronic Kidney Disease
  • CKD
  • Stage 3 or 4 Chronic Kidney Disease
  • Renal
  • Anemia
  • Oral anemia treatment
  • Hemoglobin levels
  • Blood count
  • Erythropoietin
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 80 years of age. Participants aged over 75 years but otherwise meet all other participant selection criteria will be evaluated on a case-by-case basis and can be included in this study, per discretion of Sponsor's physician representative such as medical monitor or clinical leader.
  2. Chronic Kidney Disease Stage 3 or 4 with \<11.0 grams (g)/deciliter (dL).
  3. Normal iron studies.
  4. Normal folate and vitamin B12 levels.
  5. Liver function tests within normal limits at screening.
  6. Absence of active or chronic rectal bleeding.
  7. Absence of diagnosis of age-related macular degeneration (AMD), diabetic macular edema, or diabetic proliferative retinopathy that is likely to require treatment during the trial.
  8. Female participants must not be pregnant nor breastfeeding and agree to use acceptable method of .
  9. Male participants with partners who can have children must agree to use a medically acceptable method of contraception.

Exclusion criteria

Exclusion Criteria:

  1. Seropositive for .
  2. History of chronic liver disease.
  3. History of polycystic kidney disease (PKD).
  4. Uncontrolled hypertension (diastolic BP >110 millimeter of mercury (mmHg) or systolic BP >170 mmHg at screening).
  5. Class III or IV congestive heart failure.
  6. Recent myocardial infarction or acute coronary syndrome.
  7. History of myelodysplastic syndrome.
  8. Any history of or a known genetic predisposition for developing cancer (for example, with diagnostic markers suggesting a genetic predisposition of cancer) except for curatively resected basal cell carcinoma of skin, squamous cell carcinoma of skin, cervical carcinoma in situ, or resected benign colonic polyps.
  9. Active inflammatory infection or chronic inflammatory disease.
  10. Any and uncontrolled medical condition considered a high risk for participation in an study.
  11. Blood clots within 4 weeks.
  12. History of ongoing hemolysis or diagnosis of hemolytic syndrome.
  13. Known history of bone marrow fibrosis.
  14. History of hemosiderosis or hemochromatosis.
  15. Androgen therapy within 12 weeks.
  16. Red blood cell transfusion within 12 weeks.
  17. Therapy with an erythropoiesis stimulating agent (ESA) such as human recombinant erythropoietin within the past 60 days.
  18. Intravenous iron supplementation within the past 60 days.
  19. Currently taking dapsone or acetaminophen >2.6 g/day.
  20. History of prior organ transplantation.
  21. Alcohol consumption greater than 3 or more drinks per day within the past year.
  22. Use of an investigational medication or participation in an investigational study within 4 weeks preceding Day 1.
  23. Positive urine toxicology screen for a substance that has not been prescribed for the participant.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
117 participants (actual)

Study arms

  • Experimental
    Roxadustat 0.7 mg/kg BIW

    Participants will receive roxadustat 0.7 mg/kg BIW orally with doses administered at least 68 hours apart for 29 days.

    Drug: Roxadustat

  • Experimental
    Roxadustat 0.7 mg/kg TIW

    Participants will receive roxadustat 0.7 mg/kg TIW orally with doses administered at least 46 hours apart for 26 days.

    Drug: Roxadustat

  • Experimental
    Roxadustat 1.0 mg/kg BIW

    Participants will receive roxadustat 1.0 mg/kg BIW orally with doses administered at least 72 hours apart for 29 days.

    Drug: Roxadustat

  • Experimental
    Roxadustat 1.0 mg/kg TIW

    Participants will receive roxadustat 1.0 mg/kg TIW orally with doses administered at least 48 hours apart for 26 days.

    Drug: Roxadustat

  • Experimental
    Roxadustat 1.5 mg/kg BIW

    Participants will receive roxadustat 1.5 mg/kg BIW orally with doses administered at least 68 hours apart for 29 days.

    Drug: Roxadustat

  • Experimental
    Roxadustat 1.5 mg/kg TIW

    Participants will receive roxadustat 1.5 mg/kg TIW orally with doses administered at least 46 hours apart for 26 days.

    Drug: Roxadustat

  • Experimental
    Roxadustat 2.0 mg/kg BIW

    Participants will receive roxadustat 2.0 mg/kg BIW orally with doses administered at least 68 hours apart for 29 days.

    Drug: Roxadustat

  • Experimental
    Roxadustat 2.0 mg/kg TIW

    Participants will receive roxadustat 2.0 mg/kg TIW orally with doses administered at least 46 hours apart for 26 days.

    Drug: Roxadustat

  • Placebo comparator
    Placebo

    Participants will receive placebo orally, matching to the roxadustat dose, number of days per week, and duration.

    Drug: Placebo

Interventions

  • Capsule

    Also known as: FG-4592

  • DrugPlacebo

    Capsule

06

What researchers measure

Primary outcomes

  1. Primary Safety Outcome Measure: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Treatment Discontinuation (Parts 1 and 2 Combined)

    An adverse event (AE) was any untoward medical event in a participant who received study drug whether or not the event is considered drug related. TEAEs defined as an AE beginning after first dose of study drug until 28 days after last dose of study drug or existing AEs that worsened after first dose of study drug until the participant's last study visit. Severe AEs defined as incapacitating, inability to perform usual activities. Drug-related TEAEs defined as TEAEs with possible, probable, or definite relationship to study drug. Serious AE criteria included death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed here. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Baseline up to Week 16 (End of Study (EoS])

  2. Co-Primary Efficacy Outcome Measure: Change From Baseline in Hb at Day 26-29 (End of Treatment)

    Mean Hb change from baseline was analyzed by treatment group and study visit. Baseline was defined as the mean of last 3 available values prior to the first dose.

    Time frame: Baseline, End of Treatment (EoT) (Day 26 for TIW Dosing or Day 29 for BIW Dosing)

  3. Co-Primary Efficacy Outcome Measure: Change From Baseline in Hb at Week 8 (2 Weeks of Follow Up)

    Mean Hb change from baseline was analyzed by treatment group and study visit. Baseline is defined as the mean of last 3 available values prior to the first dose.

    Time frame: Baseline, Week 8 (2 Weeks of Follow Up)

Secondary outcomes

  1. Number of Participants With a Hemoglobin Response (Not Due to a RBC Transfusion or IV Iron Supplementation During Treatment)

    Hb response defined as an increase in Hb from baseline by ≥1.0 g/dL (not due to red blood cell transfusion or IV iron supplementation during treatment). The baseline for Hb was defined as the mean of the last 3 available Hb values obtained prior to the first dose.

    Time frame: Baseline up to Day 26-29 (EoT), up to Week 8 (2 weeks of follow up), and up to Week 16 (EoS, 4 weeks of follow up)

  2. Plasma Roxadustat Concentration (Part 2)

    Time frame: Predose on Days 3 (TIW dose groups) or 4 (BIW dose groups), 8, 15, 22, and 26 (TIW dose groups) or 29 (BIW dose groups)

  3. Change From Baseline in Plasma Erythropoietin in Part 1 Participants at Day 26 or Day 29

    Baseline is defined as the last value obtained prior to the first dose.

    Time frame: Baseline (Day 1), 1, 2, 3, 4, 6, 8, 12, 18, 24, 48, and 72 hours on Day 26 (TIW Dosing) or Day 29 (BIW Dosing)

  4. Change From Baseline in Plasma Erythropoietin in Part 2 Participants at 4, 8, 12, and 24 Hours on Day 1

    Baseline is defined as the last value obtained prior to the first dose.

    Time frame: Baseline, 4, 8, 12, and 24 hours on Day 1

07

Results

Posted Nov 19, 2021

Participant flow

Part 1 (up to Day 57)
Participant flow — Part 1 (up to Day 57)
MilestoneRoxadustat 0.7 Milligrams/Kilograms (mg/kg) BIWRoxadustat 0.7 mg/kg TIWRoxadustat 1.0 mg/kg BIWRoxadustat 1.0 mg/kg TIWRoxadustat 1.5 mg/kg BIWRoxadustat 1.5 mg/kg TIWRoxadustat 2.0 mg/kg BIWRoxadustat 2.0 mg/kg TIWPlacebo
Started001210001210
Safety population00129001210
Efficacy evaluable (ee) population005500016
Pharmacokinetic (pk) population005300120
Completed008400019
Not completed004600111
Withdrew: Adverse event000100000
Withdrew: Withdrawal by subject001100000
Withdrew: Sponsor decision003400111
Part 2 (up to Day 114)
Participant flow — Part 2 (up to Day 114)
MilestoneRoxadustat 0.7 Milligrams/Kilograms (mg/kg) BIWRoxadustat 0.7 mg/kg TIWRoxadustat 1.0 mg/kg BIWRoxadustat 1.0 mg/kg TIWRoxadustat 1.5 mg/kg BIWRoxadustat 1.5 mg/kg TIWRoxadustat 2.0 mg/kg BIWRoxadustat 2.0 mg/kg TIWPlacebo
Started1013001011101018
Safety population1013001011101018
Ee population1012001011101011
Pk population101300101110100
Completed1013001011101017
Not completed000000001
Withdrew: Adverse event000000001

Outcome measures

PrimaryPrimary Safety Outcome Measure: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Treatment Discontinuation (Parts 1 and 2 Combined)

An adverse event (AE) was any untoward medical event in a participant who received study drug whether or not the event is considered drug related. TEAEs defined as an AE beginning after first dose of study drug until 28 days after last dose of study drug or existing AEs that worsened after first dose of study drug until the participant's last study visit. Severe AEs defined as incapacitating, inability to perform usual activities. Drug-related TEAEs defined as TEAEs with possible, probable, or definite relationship to study drug. Serious AE criteria included death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed here. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Baseline up to Week 16 (End of Study (EoS])
Reported as:
Count of participants · Participants
Primary Safety Outcome Measure: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Treatment Discontinuation (Parts 1 and 2 Combined)
ParticipantsRoxadustat 0.7 mg/kg BIWRoxadustat 0.7 mg/kg TIWRoxadustat 1.0 mg/kg BIWRoxadustat 1.0 mg/kg TIWRoxadustat 1.5 mg/kg BIWRoxadustat 1.5 mg/kg TIWRoxadustat 2.0 mg/kg BIWRoxadustat 2.0 mg/kg TIWPlacebo
Any TEAEs3975977513
Serious TEAEs040000001
Severe TEAEs031001101
Drug-Related TEAEs122133313
TEAEs Leading to Treatment Discontinuation000100101
PrimaryCo-Primary Efficacy Outcome Measure: Change From Baseline in Hb at Day 26-29 (End of Treatment)

Mean Hb change from baseline was analyzed by treatment group and study visit. Baseline was defined as the mean of last 3 available values prior to the first dose.

Time frame:
Baseline, End of Treatment (EoT) (Day 26 for TIW Dosing or Day 29 for BIW Dosing)
Reported as:
Mean · g/dL
Co-Primary Efficacy Outcome Measure: Change From Baseline in Hb at Day 26-29 (End of Treatment)
g/dLRoxadustat 0.7 mg/kg BIWRoxadustat 0.7 mg/kg TIWRoxadustat 1.0 mg/kg BIWRoxadustat 1.0 mg/kg TIWRoxadustat 1.5 mg/kg BIWRoxadustat 1.5 mg/kg TIWRoxadustat 2.0 mg/kg BIWRoxadustat 2.0 mg/kg TIWPlacebo
Baseline10.32 ± 0.67810.03 ± 0.7099.18 ± 0.60010.35 ± 0.84910.28 ± 0.55110.08 ± 0.6509.97 ± 0.4309.93 ± 0.80610.10 ± 0.616
Change at Day 26-290.25 ± 0.8490.60 ± 0.7560.44 ± 0.7810.21 ± 1.0161.22 ± 1.1121.65 ± 1.0331.35 ± 0.5771.75 ± 1.200-0.05 ± 0.500
Statistical analysis
  • Roxadustat 0.7 mg/kg BIW vs Placebo · t-test, 2 sided · p = 0.2073 (Threshold for significance at 0.05 level.)
  • Roxadustat 0.7 mg/kg TIW vs Placebo · t-test, 2 sided · p = 0.0046 (Threshold for significance at 0.05 level.)
  • Roxadustat 1.0 mg/kg BIW vs Placebo · t-test, 2 sided · p = 0.0860 (Threshold for significance at 0.05 level.)
  • Roxadustat 1.0 mg/kg TIW vs Placebo · t-test, 2 sided · p = 0.4005 (Threshold for significance at 0.05 level.)
  • Roxadustat 1.5 mg/kg BIW vs Placebo · t-test, 2 sided · p = <0.0001 (Threshold for significance at 0.05 level.)
  • Roxadustat 1.5 mg/kg TIW vs Placebo · t-test, 2 sided · p = <0.0001 (Threshold for significance at 0.05 level.)
  • Roxadustat 2.0 mg/kg BIW vs Placebo · t-test, 2 sided · p = <0.0001 (Threshold for significance at 0.05 level.)
  • Roxadustat 2.0 mg/kg TIW vs Placebo · t-test, 2 sided · p = <0.0001Threshold for significance at 0.05 level.
PrimaryCo-Primary Efficacy Outcome Measure: Change From Baseline in Hb at Week 8 (2 Weeks of Follow Up)

Mean Hb change from baseline was analyzed by treatment group and study visit. Baseline is defined as the mean of last 3 available values prior to the first dose.

Time frame:
Baseline, Week 8 (2 Weeks of Follow Up)
Reported as:
Mean · g/dL
Co-Primary Efficacy Outcome Measure: Change From Baseline in Hb at Week 8 (2 Weeks of Follow Up)
g/dLRoxadustat 0.7 mg/kg BIWRoxadustat 0.7 mg/kg TIWRoxadustat 1.0 mg/kg BIWRoxadustat 1.0 mg/kg TIWRoxadustat 1.5 mg/kg BIWRoxadustat 1.5 mg/kg TIWRoxadustat 2.0 mg/kg BIWRoxadustat 2.0 mg/kg TIWPlacebo
Baseline10.32 ± 0.67810.03 ± 0.7099.18 ± 0.60010.35 ± 0.84910.28 ± 0.55110.08 ± 0.6509.97 ± 0.4309.93 ± 0.80610.10 ± 0.616
Change at Week 80.59 ± 0.8080.24 ± 0.8460.50 ± 0.3560.05 ± 1.4350.79 ± 0.9161.31 ± 0.7431.21 ± 0.6561.52 ± 0.8150.04 ± 0.684
Statistical analysis
  • Roxadustat 0.7 mg/kg BIW vs Placebo · t-test, 2 sided · p = 0.0507 (Threshold for significance at 0.05 level.)
  • Roxadustat 0.7 mg/kg TIW vs Placebo · t-test, 2 sided · p = 0.4502 (Threshold for significance at 0.05 level.)
  • Roxadustat 1.0 mg/kg BIW vs Placebo · t-test, 2 sided · p = 0.1603
  • Roxadustat 1.0 mg/kg TIW vs Placebo · t-test, 2 sided · p = 0.9816 (Threshold for significance at 0.05 level.)
  • Roxadustat 1.5 mg/kg BIW vs Placebo · t-test, 2 sided · p = 0.0139 (Threshold for significance at 0.05 level.)
  • Roxadustat 1.5 mg/kg TIW vs Placebo · t-test, 2 sided · p = <0.0001 (Threshold for significance at 0.05 level.)
  • Roxadustat 2.0 mg/kg BIW vs Placebo · t-test, 2 sided · p = 0.0001 (Threshold for significance at 0.05 level.)
  • Roxadustat 2.0 mg/kg TIW vs Placebo · t-test, 2 sided · p = <0.0001 (Threshold for significance at 0.05 level.)
SecondaryNumber of Participants With a Hemoglobin Response (Not Due to a RBC Transfusion or IV Iron Supplementation During Treatment)

Hb response defined as an increase in Hb from baseline by ≥1.0 g/dL (not due to red blood cell transfusion or IV iron supplementation during treatment). The baseline for Hb was defined as the mean of the last 3 available Hb values obtained prior to the first dose.

Time frame:
Baseline up to Day 26-29 (EoT), up to Week 8 (2 weeks of follow up), and up to Week 16 (EoS, 4 weeks of follow up)
Reported as:
Count of participants · Participants
Number of Participants With a Hemoglobin Response (Not Due to a RBC Transfusion or IV Iron Supplementation During Treatment)
ParticipantsRoxadustat 0.7 mg/kg BIWRoxadustat 0.7 mg/kg TIWRoxadustat 1.0 mg/kg BIWRoxadustat 1.0 mg/kg TIWRoxadustat 1.5 mg/kg BIWRoxadustat 1.5 mg/kg TIWRoxadustat 2.0 mg/kg BIWRoxadustat 2.0 mg/kg TIWPlacebo
Day 26-291611810793
Week 857328109116
Week 1677329109118
SecondaryPlasma Roxadustat Concentration (Part 2)
Time frame:
Predose on Days 3 (TIW dose groups) or 4 (BIW dose groups), 8, 15, 22, and 26 (TIW dose groups) or 29 (BIW dose groups)
Reported as:
Mean · nanograms (ng)/milliliter (mL)
Plasma Roxadustat Concentration (Part 2)
nanograms (ng)/milliliter (mL)Roxadustat 0.7 mg/kg BIWRoxadustat 0.7 mg/kg TIWRoxadustat 1.5 mg/kg BIWRoxadustat 1.5 mg/kg TIWRoxadustat 2.0 mg/kg BIWRoxadustat 2.0 mg/kg TIW
Day 3—394.800 ± 723.156—260.027 ± 133.524—422.700 ± 148.529
Day 428.596 ± 19.737—168.310 ± 174.426—283.067 ± 376.601—
Day 819.884 ± 18.858203.535 ± 343.167125.185 ± 223.124168.955 ± 147.019291.856 ± 376.910297.500 ± 393.134
Day 1522.997 ± 18.442195.483 ± 369.794134.116 ± 269.890247.945 ± 204.624358.400 ± 491.898175.570 ± 144.779
Day 2236.432 ± 33.587153.903 ± 173.388147.323 ± 235.302163.100 ± 167.695171.833 ± 138.575239.600 ± 324.307
Day 26—331.640 ± 435.773—223.140 ± 140.340—508.889 ± 295.228
Day 2914.332 ± 9.935—150.599 ± 233.871—193.622 ± 279.533—
SecondaryChange From Baseline in Plasma Erythropoietin in Part 1 Participants at Day 26 or Day 29

Baseline is defined as the last value obtained prior to the first dose.

Time frame:
Baseline (Day 1), 1, 2, 3, 4, 6, 8, 12, 18, 24, 48, and 72 hours on Day 26 (TIW Dosing) or Day 29 (BIW Dosing)
Reported as:
Mean · milli-international units (mIU)/mL
Change From Baseline in Plasma Erythropoietin in Part 1 Participants at Day 26 or Day 29
milli-international units (mIU)/mLRoxadustat 1.0 mg/kg BIWRoxadustat 1.0 mg/kg TIWRoxadustat 2.0 mg/kg BIWRoxadustat 2.0 mg/kg TIWPlacebo
Day 1, Baseline13.46 ± 5.6913.30 ± 6.599.00 ± NA8.50 ± 3.9613.75 ± 4.53
Change at Day 26, 1 Hour—-1.50 ± 1.41—0.00 ± NA0.17 ± 0.21
Change at Day 26, 2 Hour—-0.85 ± 1.91—-0.60 ± NA0.67 ± 1.47
Change at Day 26, 3 Hour—-0.95 ± 1.34—2.30 ± NA-1.27 ± 3.15
Change at Day 26, 4 Hour—-0.45 ± 0.07—29.70 ± NA0.50 ± 4.24
Change at Day 26, 6 Hour—8.05 ± 11.81—132.80 ± NA0.33 ± 3.80
Change at Day 26, 8 Hour—57.95 ± 63.29—462.00 ± NA0.20 ± 1.18
Change at Day 26, 12 Hour—81.80 ± 81.03—492.00 ± NA-1.30 ± 1.71
Change at Day 26, 18 Hour—37.30 ± 13.01—176.90 ± NA0.87 ± 1.07
Change at Day 26, 24 Hour—22.35 ± 19.73—33.90 ± NA2.60 ± 5.46
Change at Day 26, 48 Hour—0.55 ± 10.39—-0.50 ± NA-7.50 ± 2.40
Change at Day 26, 72 Hour—-2.85 ± 5.02—-1.50 ± NA-0.60 ± 1.27
Change at Day 29, 1 Hour-1.08 ± 1.22———-1.57 ± 1.14
Change at Day 29, 2 Hour-1.27 ± 2.23———-2.73 ± 1.85
Change at Day 29, 3 Hour-0.55 ± 1.13———-3.70 ± 2.14
Change at Day 29, 4 Hour12.03 ± 10.12———-4.90 ± 1.95
Change at Day 29, 6 Hour66.85 ± 43.07———-4.17 ± 1.27
Change at Day 29, 8 Hour135.08 ± 83.95———-2.97 ± 2.20
Change at Day 29, 12 Hour77.35 ± 43.80———-2.07 ± 1.08
Change at Day 29, 18 Hour43.80 ± 13.41———-0.20 ± 1.77
Change at Day 29, 24 Hour10.18 ± 3.16———-3.07 ± 0.96
Change at Day 29, 48 Hour-5.17 ± 4.70———-4.87 ± 2.24
Change at Day 29, 72 Hour-2.93 ± 3.91———-1.63 ± 4.71
SecondaryChange From Baseline in Plasma Erythropoietin in Part 2 Participants at 4, 8, 12, and 24 Hours on Day 1

Baseline is defined as the last value obtained prior to the first dose.

Time frame:
Baseline, 4, 8, 12, and 24 hours on Day 1
Reported as:
Mean · mIU/mL
Change From Baseline in Plasma Erythropoietin in Part 2 Participants at 4, 8, 12, and 24 Hours on Day 1
mIU/mLRoxadustat 0.7 mg/kg BIWRoxadustat 0.7 mg/kg TIWRoxadustat 1.5 mg/kg BIWRoxadustat 1.5 mg/kg TIWRoxadustat 2.0 mg/kg BIWRoxadustat 2.0 mg/kg TIWPlacebo
Baseline—8.30 ± 2.269.55 ± 3.32—10.45 ± 4.31——
Change at 4 Hour—2.80 ± 3.962.10 ± 3.54—1.00 ± 2.97——
Change at 8 Hour—66.70 ± 90.23100.40 ± 92.77—42.05 ± 36.98——
Change at 12 Hour—66.25 ± 90.16147.15 ± 128.91—201.10 ± 240.42——
Change at 24 Hour—10.05 ± 8.56107.65 ± 53.25—461.05 ± 589.80——

Adverse events

Collected over Baseline up to Week 16 (EoS). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roxadustat 0.7 mg/kg BIW—0/10 (0%)3/10 (30%)
Roxadustat 0.7 mg/kg TIW—4/13 (30.8%)9/13 (69.2%)
Roxadustat 1.0 mg/kg BIW—0/12 (0%)7/12 (58.3%)
Roxadustat 1.0 mg/kg TIW—0/9 (0%)5/9 (55.6%)
Roxadustat 1.5 mg/kg BIW—0/10 (0%)9/10 (90%)
Roxadustat 1.5 mg/kg TIW—0/11 (0%)7/11 (63.6%)
Roxadustat 2.0 mg/kg BIW—0/11 (0%)7/11 (63.6%)
Roxadustat 2.0 mg/kg TIW—0/12 (0%)5/12 (41.7%)
Placebo—1/28 (3.6%)12/28 (42.9%)
Most frequent serious events
Most frequent serious events
EventRoxadustat 0.7 mg/kg BIWRoxadustat 0.7 mg/kg TIWRoxadustat 1.0 mg/kg BIWRoxadustat 1.0 mg/kg TIWRoxadustat 1.5 mg/kg BIWRoxadustat 1.5 mg/kg TIWRoxadustat 2.0 mg/kg BIWRoxadustat 2.0 mg/kg TIWPlacebo
Arteriovenous fistula siteInjury, poisoning and procedural complications0/101/130/120/90/100/110/110/120/28
Femoral neck fractureInjury, poisoning and procedural complications0/101/130/120/90/100/110/110/120/28
Non-cardiac chest painGeneral disorders0/101/130/120/90/100/110/110/120/28
DyspnoeaRespiratory, thoracic and mediastinal disorders0/101/130/120/90/100/110/110/120/28
PericarditisCardiac disorders0/100/130/120/90/100/110/110/121/28
Renal failure acuteRenal and urinary disorders0/100/130/120/90/100/110/110/121/28
Most frequent other events
Showing 10 of 92
Most frequent other events
EventRoxadustat 0.7 mg/kg BIWRoxadustat 0.7 mg/kg TIWRoxadustat 1.0 mg/kg BIWRoxadustat 1.0 mg/kg TIWRoxadustat 1.5 mg/kg BIWRoxadustat 1.5 mg/kg TIWRoxadustat 2.0 mg/kg BIWRoxadustat 2.0 mg/kg TIWPlacebo
HeadacheNervous system disorders0/101/130/121/93/101/110/110/121/28
DiarrhoeaGastrointestinal disorders0/103/132/121/91/100/111/110/122/28
Back painMusculoskeletal and connective tissue disorders0/100/130/122/91/100/111/110/121/28
HyperkalaemiaMetabolism and nutrition disorders1/100/130/120/92/101/110/110/120/28
HyperuricaemiaMetabolism and nutrition disorders0/100/130/120/90/102/110/110/120/28
FatigueGeneral disorders0/100/131/121/90/100/112/110/120/28
Renal impairmentRenal and urinary disorders0/100/130/120/90/102/110/110/120/28
ProstatitisReproductive system and breast disorders0/60/60/41/60/40/10/30/30/16
NauseaGastrointestinal disorders0/100/130/121/90/100/110/110/121/28
Gastrointestinal disorderGastrointestinal disorders0/100/130/121/90/100/110/110/120/28

Baseline characteristics

Part 1 and Part 2 Safety Population: Participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Roxadustat 0.7 mg/kg BIWRoxadustat 0.7 mg/kg TIWRoxadustat 1.0 mg/kg BIWRoxadustat 1.0 mg/kg TIWRoxadustat 1.5 mg/kg BIWRoxadustat 1.5 mg/kg TIWRoxadustat 2.0 mg/kg BIWRoxadustat 2.0 mg/kg TIWPlaceboTotal
Mean64.6 ± 4.960.6 ± 9.269.5 ± 7.767.0 ± 8.463.8 ± 8.863.5 ± 6.464.3 ± 9.066.8 ± 7.868.6 ± 6.265.8 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Roxadustat 0.7 mg/kg BIWRoxadustat 0.7 mg/kg TIWRoxadustat 1.0 mg/kg BIWRoxadustat 1.0 mg/kg TIWRoxadustat 1.5 mg/kg BIWRoxadustat 1.5 mg/kg TIWRoxadustat 2.0 mg/kg BIWRoxadustat 2.0 mg/kg TIWPlaceboTotal
Female4783610891267
Male664641331649
08

Study locations

34 sites
  • Peoria, Arizona 85381, United States
  • Tempe, Arizona 85284, United States
  • Los Angeles, California 90095, United States
  • Mission Viejo, California 92691, United States
  • Sacramento, California 95825, United States
  • San Diego, California 92123, United States
  • Whittier, California 90603, United States
  • Arvada, Colorado 80002, United States
  • Westminster, Colorado 80031, United States
  • Middlebury, Connecticut 06762, United States
  • Ocala, Florida 34471, United States
  • Panama City, Florida 32401, United States
  • Pembroke Pines, Florida 33028, United States
  • Tampa, Florida 33614, United States
  • Augusta, Georgia 30901, United States
  • Chicago, Illinois 60616, United States
  • Evergreen Park, Illinois 60805, United States
  • Wichita, Kansas 67214, United States
  • Louisville, Kentucky 40202, United States
  • Baton Rouge, Louisiana 70809, United States
  • Shreveport, Louisiana 71101, United States
  • Detroit, Michigan 48236, United States
  • Lincoln, Nebraska 68510, United States
  • Las Vegas, Nevada 89106, United States
  • Flushing, New York 11355, United States
  • Winston-Salem, North Carolina 27103, United States
  • Cleveland, Ohio 44109, United States
  • Toledo, Ohio 43606, United States
  • Medford, Oregon 97504, United States
  • Wynnewood, Pennsylvania 19096, United States
  • Columbia, South Carolina 29203, United States
  • Orangeburg, South Carolina 29118, United States
  • Chattanooga, Tennessee 37404, United States
  • Houston, Texas 77036, United States
09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
  • Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, Leong R, Hemmerich S, Yu KH, Neff TB. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015 Oct;30(10):1665-73. doi: 10.1093/ndt/gfv302. Epub 2015 Aug 3. PubMed 26238121 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2006 to primary completion in Jun 2010, 43 months.

Results were first posted in Nov 2021, 11 years 4 months after primary completion.

Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 43 months is above that.

Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2008
First posted
Sep 29, 2008
StartActual
Nov 1, 2006
Primary completionActual
Jun 21, 2010
CompletionActual
Jun 21, 2010
Results first posted
Nov 19, 2021
Last update
Nov 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00761657
Lead sponsor
FibroGen
Collaborators
Astellas Pharma Inc
Responsible party
Sponsor
First posted
Sep 29, 2008
Start date
Nov 1, 2006
Primary completion
Jun 21, 2010
Completion
Jun 21, 2010
Results posted
Nov 19, 2021
Last update
Nov 19, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion